NM_001077365.2(POMT1):c.1827T>C (p.Asp609=) AND multiple conditions
- Germline classification:
- Likely benign (1 submission)
- Last evaluated:
- May 29, 2023
- Review status:
- Somatic classification
of clinical impact: - None
- Review status:
- Somatic classification
of oncogenicity: - None
- Review status:
- Record status:
- current
- Accession:
- RCV003790931.2
Allele description [Variation Report for NM_001077365.2(POMT1):c.1827T>C (p.Asp609=)]
NM_001077365.2(POMT1):c.1827T>C (p.Asp609=)
Condition(s)
- Name:
- Autosomal recessive limb-girdle muscular dystrophy type 2K
- Synonyms:
- MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2K; Limb-girdle muscular dystrophy-dystroglycanopathy, type C1
- Identifiers:
- MONDO: MONDO:0012248; MedGen: C1836373; Orphanet: 86812; OMIM: 609308
- Name:
- Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1 (MDDGB1)
- Synonyms:
- MUSCULAR DYSTROPHY, CONGENITAL, POMT1-RELATED; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 1
- Identifiers:
- MONDO: MONDO:0013159; MedGen: C5436962; OMIM: 613155
-
MRPS15[gene] (35)
ClinVar
-
Homo sapiens family with sequence similarity 135, member B, mRNA (cDNA clone MGC...
Homo sapiens family with sequence similarity 135, member B, mRNA (cDNA clone MGC:33221 IMAGE:5266568), complete cdsgi|71296806|gb|BC037288.1|Nucleotide
-
65840[uid] (1)
Taxonomy
-
Homo sapiens peroxisomal biogenesis factor 5 (PEX5), transcript variant 13, mRNA
Homo sapiens peroxisomal biogenesis factor 5 (PEX5), transcript variant 13, mRNAgi|1757649824|ref|NM_001351132.2|Nucleotide
-
Streptomyces mutabilis strain JCM 4400 sequence315, whole genome shotgun sequenc...
Streptomyces mutabilis strain JCM 4400 sequence315, whole genome shotgun sequencegi|1913001122|ref|NZ_BMTT01000315.1 |WGS:NZ_BMTT01|sequence315Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...Assertion and evidence details
Last Updated: Sep 29, 2024